EP
TSHA icon

Essential Partners’s Taysha Gene Therapies TSHA Stock Holding History

Essential Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.59K Hold
327
– – ﹤0.01% 2006
2026
Q2 		$2.23K Hold
327
– – ﹤0.01% 1930
2026
Q1 		$1.46K Hold
327
– – ﹤0.01% 2110
2025
Q4 		$1.8K Hold
327
– – ﹤0.01% 1841
2025
Q3 		$1.07K Hold
327
– – ﹤0.01% 2000
2025
Q2 		$755 Buy
+327
New +$710 ﹤0.01% 1581

Other funds holding TSHA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's TSHA Position: Q3 2026 in Review

Essential Partners held its Taysha Gene Therapies (TSHA) position steady in Q3 2026 at 327 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

Essential Partners first reported a position in TSHA in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.23K in Q2 2026. 7 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Essential Partners held 327 shares of Taysha Gene Therapies worth $1.59K as of Q3 2026.
  • Essential Partners left its Taysha Gene Therapies share count unchanged in Q3 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2006 holding.
  • Essential Partners first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Taysha Gene Therapies position peaked at $2.23K in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.